IL280550B2 - A pharmaceutical composition for safe and effective treatment of knee and/or hip pain - Google Patents

A pharmaceutical composition for safe and effective treatment of knee and/or hip pain

Info

Publication number
IL280550B2
IL280550B2 IL280550A IL28055021A IL280550B2 IL 280550 B2 IL280550 B2 IL 280550B2 IL 280550 A IL280550 A IL 280550A IL 28055021 A IL28055021 A IL 28055021A IL 280550 B2 IL280550 B2 IL 280550B2
Authority
IL
Israel
Prior art keywords
pain
antibody
pharmaceutical composition
subject
ngf
Prior art date
Application number
IL280550A
Other languages
English (en)
Hebrew (he)
Other versions
IL280550B1 (en
IL280550A (en
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IL280550A publication Critical patent/IL280550A/en
Publication of IL280550B1 publication Critical patent/IL280550B1/en
Publication of IL280550B2 publication Critical patent/IL280550B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
IL280550A 2018-08-10 2019-08-09 A pharmaceutical composition for safe and effective treatment of knee and/or hip pain IL280550B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862717435P 2018-08-10 2018-08-10
US201862764816P 2018-08-15 2018-08-15
PCT/US2019/045970 WO2020033872A1 (en) 2018-08-10 2019-08-09 A pharmaceutical composition for safe and effective treatment of knee and/or hip pain

Publications (3)

Publication Number Publication Date
IL280550A IL280550A (en) 2021-03-25
IL280550B1 IL280550B1 (en) 2025-02-01
IL280550B2 true IL280550B2 (en) 2025-06-01

Family

ID=67811008

Family Applications (1)

Application Number Title Priority Date Filing Date
IL280550A IL280550B2 (en) 2018-08-10 2019-08-09 A pharmaceutical composition for safe and effective treatment of knee and/or hip pain

Country Status (10)

Country Link
US (2) US11472870B2 (https=)
EP (1) EP3833687A1 (https=)
JP (1) JP7460598B2 (https=)
KR (1) KR20210043624A (https=)
CN (1) CN112839956A (https=)
AU (1) AU2019318556A1 (https=)
CA (1) CA3108697A1 (https=)
IL (1) IL280550B2 (https=)
MX (1) MX2021001549A (https=)
WO (1) WO2020033872A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7532290B2 (ja) * 2021-03-09 2024-08-13 エヌ・ティ・ティ・コミュニケーションズ株式会社 患者追跡調査支援システム、患者追跡調査支援方法、支援制御装置、端末装置およびプログラム
EP4433500A1 (en) 2021-11-19 2024-09-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for reducing centralized pain
US20240002491A1 (en) * 2022-04-27 2024-01-04 Regeneron Pharmaceuticals, Inc. Methods for selecting patients for treatment with an ngf antagonist

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006110883A2 (en) * 2005-04-11 2006-10-19 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
WO2009023540A1 (en) * 2007-08-10 2009-02-19 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human nerve growth factor
US20110014208A1 (en) * 2007-08-10 2011-01-20 Regeneron Pharmaceuticals, Inc. Method of Treating Osteoarthritis with an Antibody to NGF
WO2011049758A1 (en) * 2009-10-09 2011-04-28 Amgen Inc. Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
WO2011116090A1 (en) * 2010-03-17 2011-09-22 Abbott Research B.V. Anti-nerve growth factor (ngf) antibody compositions
WO2013184871A1 (en) * 2012-06-06 2013-12-12 Zoetis Llc Caninized anti-ngf antibodies and methods thereof
WO2018102294A1 (en) * 2016-11-29 2018-06-07 Regeneron Pharmaceuticals, Inc. A pharmaceutical composition for averting opioid addiction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN101014364B (zh) 2002-12-24 2012-01-18 里纳特神经系统学公司 抗ngf抗体及其使用方法
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
BR112013008366B1 (pt) 2010-10-06 2022-02-08 Regeneron Pharmaceuticals, Inc Formulações farmacêuticas líquidas estáveis contendo anticorpos anti-receptor de interleucina-4 humana alfa, e recipiente contendo as referidas formulações

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006110883A2 (en) * 2005-04-11 2006-10-19 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
WO2009023540A1 (en) * 2007-08-10 2009-02-19 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human nerve growth factor
US20110014208A1 (en) * 2007-08-10 2011-01-20 Regeneron Pharmaceuticals, Inc. Method of Treating Osteoarthritis with an Antibody to NGF
WO2011049758A1 (en) * 2009-10-09 2011-04-28 Amgen Inc. Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
WO2011116090A1 (en) * 2010-03-17 2011-09-22 Abbott Research B.V. Anti-nerve growth factor (ngf) antibody compositions
WO2013184871A1 (en) * 2012-06-06 2013-12-12 Zoetis Llc Caninized anti-ngf antibodies and methods thereof
WO2018102294A1 (en) * 2016-11-29 2018-06-07 Regeneron Pharmaceuticals, Inc. A pharmaceutical composition for averting opioid addiction

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
TISEO PAUL J ET AL,, FASINUMAB (REGN475), AN ANTIBODY AGAINST NERVE GROWTH FACTOR FOR THE TREATMENT OF PAIN: RESULTS FROM A DOUBLE-BLIND, PLACEBO-CONTROLLED EXPLORATORY STUDY IN OSTEOARTHRITIS OF THE KNEE, 18 March 2014 (2014-03-18) *
TISEO PAUL J. ET AL,, FASINUMAB (REGN475), AN ANTINERVE GROWTH FACTOR MONOCLONAL ANTIBODY, FOR THE TREATMENT OF ACUTE SCIATIC PAIN: RESULTS OF A PROOF-OF-CONCEPT STUDY, 1 August 2014 (2014-08-01) *

Also Published As

Publication number Publication date
US11472870B2 (en) 2022-10-18
JP2021533142A (ja) 2021-12-02
KR20210043624A (ko) 2021-04-21
CA3108697A1 (en) 2020-02-13
IL280550B1 (en) 2025-02-01
US20220041708A1 (en) 2022-02-10
MX2021001549A (es) 2021-04-13
WO2020033872A1 (en) 2020-02-13
JP7460598B2 (ja) 2024-04-02
EP3833687A1 (en) 2021-06-16
IL280550A (en) 2021-03-25
CN112839956A (zh) 2021-05-25
US20200048337A1 (en) 2020-02-13
AU2019318556A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
JP7744190B2 (ja) リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
US20220041708A1 (en) Pharmaceutical Composition for Safe and Effective Treatment of Knee and/or Hip Pain
JP2017528465A (ja) 乾癬性関節炎患者における構造的損傷の進行を阻害するためのｉｌ−１７アンタゴニストの使用
US11491222B2 (en) Method of treating lower back pain
KR20210122810A (ko) 청소년 특발성 관절염을 치료하기 위한 항 il-6 수용체 항체
US20220356261A1 (en) Treatment for sjögren's syndrome
AU2018361975A1 (en) Method of treating tendinopathy using interleukin-17 (IL-17) antagonists
US20250011408A1 (en) Methods and compositions for reducing centralized pain
RU2786232C2 (ru) Фармацевтическая композиция для безопасного и эффективного лечения боли колена и/или тазобедренного сустава
US20240002491A1 (en) Methods for selecting patients for treatment with an ngf antagonist
CN117203232A (zh) 用抗il-13抗体治疗特应性皮炎的方法
EA044062B1 (ru) Фармацевтическая композиция для предотвращения опиоидной зависимости
HK40011843A (en) A pharmaceutical composition for averting opioid addiction
EA041556B1 (ru) Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией подвергающихся аферезу липопротеинов